Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor–Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)

(2020) E. Shelley Hwang et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

(2020) Laura M Spring et al.   LANCET

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial

(2019) Shu-Lian Wang et al.   LANCET ONCOLOGY

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

(2019) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

(2019) Helena M Earl et al.   LANCET

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

(2019) Xavier Pivot et al.   LANCET

Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer

(2019) Hoon Sik Choi et al.   Radiation Oncology

Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients

(2019) Hiram A. Gay et al.   Practical Radiation Oncology

Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer

(2019) William H. Ward et al.   ANNALS OF SURGICAL ONCOLOGY

Predictors of Residual Disease After Breast Conservation Surgery

(2018) Lisa J. Findlay-Shirras et al.   ANNALS OF SURGICAL ONCOLOGY

Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer

(2018) Saulo Brito Silva et al.   BREAST

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

(2018) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR

(2018) Debra L. Monticciolo et al.   Journal of the American College of Radiology

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

(2018) Hiroji Iwata et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

(2016) A. Murray Brunt et al.   RADIOTHERAPY AND ONCOLOGY

Time to Surgery and Breast Cancer Survival in the United States

(2016) Richard J. Bleicher et al.   JAMA Oncology

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

(2016) Laura M. Spring et al.   JAMA Oncology

Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients

(2015) Rachel A. Sanford et al.   ANNALS OF SURGICAL ONCOLOGY

Addressing overtreatment of screen detected DCIS; the LORIS trial

(2015) Adele Francis et al.   EUROPEAN JOURNAL OF CANCER

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study

(2015) Lotte E. Elshof et al.   EUROPEAN JOURNAL OF CANCER

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial

(2015) Ian H Kunkler et al.   LANCET ONCOLOGY

Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

(2013) Kevin S. Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

(2013) Jack Cuzick et al.   LANCET

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials

(2013) Joanne S Haviland et al.   LANCET ONCOLOGY

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial

(2012) Norikazu Masuda et al.   LANCET ONCOLOGY

Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer

(2011) Norikazu Masuda et al.   BREAST CANCER RESEARCH AND TREATMENT

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015)

(2011)   RADIOTHERAPY AND ONCOLOGY

Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer

(2010) Timothy J. Whelan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial

(2009) Heather A. Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

Intervals Longer Than 20 Weeks From Breast-Conserving Surgery to Radiation Therapy Are Associated With Inferior Outcome for Women With Early-Stage Breast Cancer Who Are Not Receiving Chemotherapy

(2008) Ivo A. Olivotto et al.   JOURNAL OF CLINICAL ONCOLOGY